TITLE:
Study of Itraconazole in Patients With Advanced HIV Infection

CONDITION:
HIV Infections

INTERVENTION:
Itraconazole

SUMMARY:

      To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma
      concentration range comparable to that obtained after currently used oral dosages of
      itraconazole oral solution; and to obtain preliminary safety data in patients with advanced
      HIV disease.
    

DETAILED DESCRIPTION:

      Patients will receive intravenous itraconazole solution twice daily for 2 days and then once
      daily for five additional days. Patients then randomized to receive twice-daily or
      once-daily itraconazole oral solution for an additional 28 days.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

        Antiretroviral therapy providing patient has already been on a stable, unchanged regimen
        for 8 weeks prior to study entry.

        Patients must have:

          -  Documented HIV infection.

          -  CD4 lymphocyte count < 300 cells/mm3.

          -  No clinically significant abnormalities, elicited by history and physical
             examination.

          -  No clinically significant abnormalities in blood count, biochemical profile, or
             urinalysis within 2 weeks of study entry.

          -  Negative urine screening.

          -  No clinically significant abnormalities of electrocardiogram.

        Prior Medication:

        Allowed:

        Antiretroviral therapy providing patient has been on a stable, unchanged regimen for 8
        weeks prior to study entry.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms and conditions are excluded:

          -  Acute opportunistic infection or other significant concurrent illness that would
             preclude participation for the required 36 days.

          -  Unable to swallow oral solution.

          -  Obesity greater than 25% of ideal body weight.

        Concurrent Medication:

        Excluded:

          -  Rifampin.

          -  Rifabutin.

          -  Phenobarbital.

          -  Phenytoin.

          -  Carbamazepine.

          -  Digoxin.

          -  Warfarin.

          -  Midazolam.

          -  Triazolam.

          -  Terfenadine.

          -  Astemizole.

          -  Cisapride.

          -  H2 blockers.

          -  Omeprazole.

          -  Continual antacids.

          -  Didanosine.

          -  Any medication known to affect absorption, metabolism or excretion of imidazole or
             azole compounds.

        Patients with the following prior symptoms and conditions are excluded:

          -  Previous hypersensitivity to azole antifungals.

          -  History of surgical procedure that may interfere with absorption of itraconazole.

          -  History of significant blood loss in the previous 30 days.

        Prior Medication:

        Excluded:

        Excluded within 15 days prior to study entry:

          -  Rifampin.

          -  Rifabutin.

          -  Phenobarbital.

          -  Phenytoin.

          -  Carbamazepine.

          -  Digoxin.

          -  Warfarin.

          -  Midazolam.

          -  Triazolam.

        Excluded within 8 weeks prior to study entry:

          -  Change in antiretroviral therapy.

        Risk Behavior:

        Excluded:

        Patients who chew tobacco or regularly smoke more than 10 cigarettes per day.
      
